657 related articles for article (PubMed ID: 29110146)
21. Endogenous pro-resolving and anti-inflammatory lipid mediators: the new hope of atherosclerotic diseases.
Chen Y; Wang J; Nie R; Zhou S
Med Hypotheses; 2008 Aug; 71(2):237-40. PubMed ID: 18448265
[TBL] [Abstract][Full Text] [Related]
22. Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis.
Ho KJ; Spite M; Owens CD; Lancero H; Kroemer AH; Pande R; Creager MA; Serhan CN; Conte MS
Am J Pathol; 2010 Oct; 177(4):2116-23. PubMed ID: 20709806
[TBL] [Abstract][Full Text] [Related]
23. The role of non-resolving inflammation in atherosclerosis.
Kasikara C; Doran AC; Cai B; Tabas I
J Clin Invest; 2018 Jul; 128(7):2713-2723. PubMed ID: 30108191
[TBL] [Abstract][Full Text] [Related]
24. Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques.
Ogawa M; Magata Y; Kato T; Hatano K; Ishino S; Mukai T; Shiomi M; Ito K; Saji H
J Nucl Med; 2006 Nov; 47(11):1845-50. PubMed ID: 17079818
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular disease management through restrained inflammatory responses.
Jabir NR; Tabrez S
Curr Pharm Des; 2016; 22(7):940-6. PubMed ID: 26648461
[TBL] [Abstract][Full Text] [Related]
26. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
Chapman MJ
Pharmacol Ther; 2007 Jan; 113(1):184-96. PubMed ID: 17070923
[TBL] [Abstract][Full Text] [Related]
27. Mesenchymal Stem Cells Stabilize Atherosclerotic Vulnerable Plaque by Anti-Inflammatory Properties.
Wang SS; Hu SW; Zhang QH; Xia AX; Jiang ZX; Chen XM
PLoS One; 2015; 10(8):e0136026. PubMed ID: 26288013
[TBL] [Abstract][Full Text] [Related]
28. Identifying Vulnerable Atherosclerotic Plaque in Rabbits Using DMSA-USPIO Enhanced Magnetic Resonance Imaging to Investigate the Effect of Atorvastatin.
Qi C; Deng L; Li D; Wu W; Gong L; Li Y; Zhang Q; Zhang T; Zhang C; Zhang Y
PLoS One; 2015; 10(5):e0125677. PubMed ID: 25973795
[TBL] [Abstract][Full Text] [Related]
29. Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.
Bai W; Zheng X; Zhou L; Li H
Can J Physiol Pharmacol; 2012 Feb; 90(2):131-9. PubMed ID: 22309388
[TBL] [Abstract][Full Text] [Related]
30. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice.
Arnaud C; Poulain L; Lévy P; Dematteis M
Atherosclerosis; 2011 Dec; 219(2):425-31. PubMed ID: 21917260
[TBL] [Abstract][Full Text] [Related]
31. Research Progress on the Relationship between Atherosclerosis and Inflammation.
Zhu Y; Xian X; Wang Z; Bi Y; Chen Q; Han X; Tang D; Chen R
Biomolecules; 2018 Aug; 8(3):. PubMed ID: 30142970
[TBL] [Abstract][Full Text] [Related]
32. Role of EPA in Inflammation: Mechanisms, Effects, and Clinical Relevance.
Crupi R; Cuzzocrea S
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204743
[TBL] [Abstract][Full Text] [Related]
33. Anti-inflammatory effects of anti-platelet treatment in atherosclerosis.
Arazi HC; Badimon JJ
Curr Pharm Des; 2012; 18(28):4311-25. PubMed ID: 22236116
[TBL] [Abstract][Full Text] [Related]
34. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization.
Stoll G; Bendszus M
Stroke; 2006 Jul; 37(7):1923-32. PubMed ID: 16741184
[TBL] [Abstract][Full Text] [Related]
35. Pro-resolving mediators in the regulation of periodontal disease.
Van Dyke TE
Mol Aspects Med; 2017 Dec; 58():21-36. PubMed ID: 28483532
[TBL] [Abstract][Full Text] [Related]
36. Periodontal pathogens invade gingiva and aortic adventitia and elicit inflammasome activation in αvβ6 integrin-deficient mice.
Velsko IM; Chukkapalli SS; Rivera-Kweh MF; Zheng D; Aukhil I; Lucas AR; Larjava H; Kesavalu L
Infect Immun; 2015 Dec; 83(12):4582-93. PubMed ID: 26371120
[TBL] [Abstract][Full Text] [Related]
37. Resolvins: Current understanding and future potential in the control of inflammation.
Bannenberg GL
Curr Opin Drug Discov Devel; 2009 Sep; 12(5):644-58. PubMed ID: 19736623
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice.
Rinne P; Silvola JM; Hellberg S; Ståhle M; Liljenbäck H; Salomäki H; Koskinen E; Nuutinen S; Saukko P; Knuuti J; Saraste A; Roivainen A; Savontaus E
Arterioscler Thromb Vasc Biol; 2014 Jul; 34(7):1346-54. PubMed ID: 24790139
[TBL] [Abstract][Full Text] [Related]
39. Lipoxins and new lipid mediators in the resolution of inflammation.
Schwab JM; Serhan CN
Curr Opin Pharmacol; 2006 Aug; 6(4):414-20. PubMed ID: 16750421
[TBL] [Abstract][Full Text] [Related]
40. Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin.
Salic K; Morrison MC; Verschuren L; Wielinga PY; Wu L; Kleemann R; Gjorstrup P; Kooistra T
Atherosclerosis; 2016 Jul; 250():158-65. PubMed ID: 27236706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
